SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision
📖

JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-jnk-p38-mapk-therapeut
Related Entities
companies-pd-jnk-p38-mapk-therapeutic-companies
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
82
Outgoing
82
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Linked Artifacts (158)
related🧫Macroautophagy Dysfunction in PD - Experiment Design70%
related🧫Macroautophagy Dysfunction in PD - Experiment Design70%
related🧫CRISPR Gene Correction Approaches for CBS/PSP60%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%
related🧫Experiment: Multi-Ethnic PD GWAS60%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%
related🧫Prodromal Parkinson's Disease Biomarker Development — E60%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%
related🧫Cytochrome Therapeutics60%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%
related🧫Ferroptosis Validation in Parkinson's Disease60%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De60%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%
related🧫AAV-LRRK2 IND-Enabling Study Design60%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%
related🧫Alpha-Synuclein Seed Amplification Assay Validation60%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%
related🧫Validation: Membrane-Nucleation in iPSC Neurons60%
related🧫Antiviral Therapy Trial for Parkinson's Disease60%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%
related🧫Parkinson's Disease Subtype Classification — Precision 60%
related🧫Combination Therapy Sequencing in Parkinson's Disease60%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%
related🧫MLCS Quantification in Parkinson's Disease60%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%
related🧫Alpha-Synuclein Seed Amplification Assay Validation54%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%
related🧫Parkinson's Disease Subtype Classification — Precision 54%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%
related🧫Ferroptosis Validation in Parkinson's Disease54%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%
related🧫Experiment: Multi-Ethnic PD GWAS54%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%
related🧫Antiviral Therapy Trial for Parkinson's Disease54%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%
related🧫Combination Therapy Sequencing in Parkinson's Disease54%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%
related🧫Validation: Membrane-Nucleation in iPSC Neurons54%
related🧫AAV-LRRK2 IND-Enabling Study Design54%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%
related🧫MLCS Quantification in Parkinson's Disease54%
related🧫Cytochrome Therapeutics54%
related🧫CRISPR Gene Correction Approaches for CBS/PSP54%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%
related🧫Prodromal Parkinson's Disease Biomarker Development — E54%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De54%
related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%
related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%
related🔬What are the most promising therapeutic strategies for targe50%
mentions🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬How does metabolic reprogramming (glucose metabolism shifts,50%
related🔬What cell types are most vulnerable in Alzheimers Disease ba50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What cell types are most vulnerable in Alzheimer's Dise50%
related🔬CRISPR-based therapeutic approaches for neurodegenerative di50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬What are the mechanisms by which tau pathology spreads throu50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬Multiple NDDs converge on autophagy-lysosome dysfunction. Ar50%
related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬TDP-43 undergoes liquid-liquid phase separation that becomes50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%
mentions🔬What are the mechanisms by which tau pathology spreads throu40%
mentions🔬Analyze circuit-level changes in neurodegeneration using All40%
mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%
mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%
mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di40%
mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%
related🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m40%
mentions🔬What are the most promising therapeutic strategies for targe40%
mentions🔬Multiple NDDs converge on autophagy-lysosome dysfunction. Ar40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
mentions🔬What are the mechanisms underlying apoe4 structural biology 40%
mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%
mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬Investigate prion-like spreading of tau pathology through co40%

💬 Discussion

SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub